Development of evidence‐based consensus on critical issues in the management of patients with vitiligo: A modified Delphi study

Bae, Jung Min; Jeong, Ki‐Heon; Choi, Chong Won; Park, Ji Hun; Lee, Hee Jung; Kim, Hee Jung; Lee, Sang Hoon; Oh, Sang Ho; Shin, Jeonghyun; Kang, Hee Young; Lee, Weon Ju; Ju, Hyun Jeong; Kim, Dong Hyun; Chang, Sung Eun; Lee, Dong Youn; Kim, You Chan; Choi, Gwang Seong; Kim, Ki Ho; Kim, Tae Heung; Lee, Seung−Chul; Lee, Ai Young; Hann, Seung Kyung; Lee, Mu Hyoung; Park, Chul Jong

doi:10.1111/phpp.12598

Cited by 4 publications

(3 citation statements)

References 83 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although 74.8% of all patients with vitiligo were treated at some point, our results show that at the end of 2021, more than 80% of patients were untreated, suggesting a lack of medication persistence. This may be due to potential safety concerns with long-term use of therapies, such as steroids, and/or could be an indicator of treatment dissatisfaction by patients and physicians [ 14 , 32 – 34 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis

Ramot,

Rosenberg,

Zhou

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction: Vitiligo, a chronic autoimmune skin depigmentation disease with an unpredictable course, has been associated with several comorbid autoimmune and psychological conditions. Our current understanding of vitiligo burden and management in the real world is limited. This real-world analysis presents data on vitiligo epidemiology, comorbidities, and treatment of patients in Israel.Methods: This retrospective study analyzed data from the Maccabi Health Services database. Prevalent patients with vitiligo in 2021 were matched to patients in the general population on the basis of age group, gender, and socioeconomic status. Patient demographics, vitiligo incidence and prevalence, comorbidities, and treatment patterns are reported. Data are presented as percentages, mean, median, P values, and standard mean differences (SMD). Results: In this analysis, 11,412 patients with vitiligo were matched to patients from the general population. Incidence and prevalence rates increased over time from 2005 to 2021. Compared to the general population, patients with vitiligo were more likely to have an immune-mediated comorbidity (29.7% vs 18.4% [P < 0.001; SMD 0.27]) or psychological comorbidity (18.7% vs 15.9% [P < 0.001; SMD 0.07]). Comorbidities included atopic dermatitis (patients with vitiligo vs general population 12.5% vs 8.4%), psoriasis (5.8% vs 3.6%), Hashimoto's thyroiditis (2.9% vs 1.1%), alopecia areata (2.2% vs 0.9%), depression (10.8% vs 9.5%), and sleep disorder/insomnia (5.9% vs 4.4%). Only 74.8% of all patients with vitiligo had ever received treatment, with topical corticosteroids (51.5%) and calcineurin inhibitors (36.5%) most commonly prescribed. At the end of 2021, 83.7% of patients were untreated. Conclusion: Patients with vitiligo are more likely to have various immune-related and

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and Treatment Patterns of Patients with Vitiligo: A Real-World Analysis

Ramot,

Rosenberg,

Zhou

et al. 2024

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Nonetheless, current options are limited, time-consuming, associated with significant side effects or have varying efficacy. [10][11][12][13][14][15][16][17][18][19][20][21][22][23] The cosmetic changes in vitiligo are caused by both immunological and inflammatory pathways and are associated with an increase in anxiety, stress, shame and depression, a loss of self-esteem; these profound impacts on social interactions and quality of life should also be considered. 24,25 With recent developments of biologics as an avenue to treat other autoimmune diseases have shown great promise, [26][27][28][29] this review will thus explore their use as a therapeutic treatment avenue for vitiligo.…”

Section: Introductionmentioning

confidence: 99%

“…In extensive vitiligo, monobenzone ether of hydroquinone for depigmentation is offered. Nonetheless, current options are limited, time‐consuming, associated with significant side effects or have varying efficacy 10–23 . The cosmetic changes in vitiligo are caused by both immunological and inflammatory pathways and are associated with an increase in anxiety, stress, shame and depression, a loss of self‐esteem; these profound impacts on social interactions and quality of life should also be considered 24,25 .…”

Section: Introductionmentioning

confidence: 99%

A review of JAK and IL‐23 inhibitors to treat vitiligo

et al. 2023

View full text Add to dashboard Cite

Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%–2% of the global population. Despite its well‐understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first‐line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associated with significant adverse events or can be time‐consuming. Therefore, biologics should be explored as a potential treatment for vitiligo. There are currently limited data for the use of JAK and IL‐23 inhibitors for vitiligo. A total of 25 studies were identified in the review. There is promising evidence regarding the use of JAK and IL‐23 inhibitors for the treatment of vitiligo.

show abstract